Cargando…

The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease

BACKGROUND AND PURPOSE: The polypill approach has been proposed to reduce patients’ pill burden, increase medication adherence and lower stroke incidence. However, little is known about patients’ attitudes towards polypills for cerebrovascular medication. METHODS: Based on the European Organization...

Descripción completa

Detalles Bibliográficos
Autores principales: Lehmann, Jens, Riedl, David, Sztankay, Monika, Boehme, Christian, Fischnaller, Julian, Kiechl, Stefan, Holzner, Bernhard, Knoflach, Michael, Rumpold, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292587/
https://www.ncbi.nlm.nih.gov/pubmed/34463018
http://dx.doi.org/10.1111/ene.15088
_version_ 1784749408327303168
author Lehmann, Jens
Riedl, David
Sztankay, Monika
Boehme, Christian
Fischnaller, Julian
Kiechl, Stefan
Holzner, Bernhard
Knoflach, Michael
Rumpold, Gerhard
author_facet Lehmann, Jens
Riedl, David
Sztankay, Monika
Boehme, Christian
Fischnaller, Julian
Kiechl, Stefan
Holzner, Bernhard
Knoflach, Michael
Rumpold, Gerhard
author_sort Lehmann, Jens
collection PubMed
description BACKGROUND AND PURPOSE: The polypill approach has been proposed to reduce patients’ pill burden, increase medication adherence and lower stroke incidence. However, little is known about patients’ attitudes towards polypills for cerebrovascular medication. METHODS: Based on the European Organization for Research and Treatment of Cancer Quality of Life Group questionnaire development guidelines, a questionnaire to measure patients’ attitudes towards polypills for the secondary prevention of stroke (phase I–III) was developed. In phase I, issues were generated via literature review and interviews with patients and healthcare professionals. The issues were operationalized into items in phase II. In phase III the questionnaire was validated in a large single‐centre sample, and test–retest and internal validity were evaluated. RESULTS: In phase I, 34 relevant issues were identified through literature search and interviews. Pre‐testing the questionnaire indicated high applicability and comprehensibility. The final Attitudes towards Polypills Questionnaire was tested in N = 260 patients and showed a two‐factor structure. The factors were labelled ‘concerns’ and ‘benefits’. The scales showed acceptable and good internal validity (concerns, Cronbach's α = 0.85; benefits, α = 0.93), but the scales’ test–retest validity was ambiguous. On a 0 to 3 rating scale, concerns were rated lower than benefits (mean 1.07, SD 0.69 vs. mean 1.87, SD 0.89). CONCLUSIONS: The Attitudes towards Polypills Questionnaire showed high comprehensibility and content validity to assess German language patients’ attitudes towards a polypill medication. Our data and questionnaire may aid the implementation of polypill treatments in clinical practice and can be used in the design of future clinical trials on polypill therapy. Further validation of the questionnaire is advised.
format Online
Article
Text
id pubmed-9292587
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92925872022-07-20 The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease Lehmann, Jens Riedl, David Sztankay, Monika Boehme, Christian Fischnaller, Julian Kiechl, Stefan Holzner, Bernhard Knoflach, Michael Rumpold, Gerhard Eur J Neurol Stroke BACKGROUND AND PURPOSE: The polypill approach has been proposed to reduce patients’ pill burden, increase medication adherence and lower stroke incidence. However, little is known about patients’ attitudes towards polypills for cerebrovascular medication. METHODS: Based on the European Organization for Research and Treatment of Cancer Quality of Life Group questionnaire development guidelines, a questionnaire to measure patients’ attitudes towards polypills for the secondary prevention of stroke (phase I–III) was developed. In phase I, issues were generated via literature review and interviews with patients and healthcare professionals. The issues were operationalized into items in phase II. In phase III the questionnaire was validated in a large single‐centre sample, and test–retest and internal validity were evaluated. RESULTS: In phase I, 34 relevant issues were identified through literature search and interviews. Pre‐testing the questionnaire indicated high applicability and comprehensibility. The final Attitudes towards Polypills Questionnaire was tested in N = 260 patients and showed a two‐factor structure. The factors were labelled ‘concerns’ and ‘benefits’. The scales showed acceptable and good internal validity (concerns, Cronbach's α = 0.85; benefits, α = 0.93), but the scales’ test–retest validity was ambiguous. On a 0 to 3 rating scale, concerns were rated lower than benefits (mean 1.07, SD 0.69 vs. mean 1.87, SD 0.89). CONCLUSIONS: The Attitudes towards Polypills Questionnaire showed high comprehensibility and content validity to assess German language patients’ attitudes towards a polypill medication. Our data and questionnaire may aid the implementation of polypill treatments in clinical practice and can be used in the design of future clinical trials on polypill therapy. Further validation of the questionnaire is advised. John Wiley and Sons Inc. 2021-09-09 2021-12 /pmc/articles/PMC9292587/ /pubmed/34463018 http://dx.doi.org/10.1111/ene.15088 Text en © 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Stroke
Lehmann, Jens
Riedl, David
Sztankay, Monika
Boehme, Christian
Fischnaller, Julian
Kiechl, Stefan
Holzner, Bernhard
Knoflach, Michael
Rumpold, Gerhard
The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease
title The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease
title_full The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease
title_fullStr The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease
title_full_unstemmed The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease
title_short The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease
title_sort attitude towards polypills questionnaire (appq): a phase i–iii development and validation study in patients with cerebrovascular disease
topic Stroke
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292587/
https://www.ncbi.nlm.nih.gov/pubmed/34463018
http://dx.doi.org/10.1111/ene.15088
work_keys_str_mv AT lehmannjens theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT riedldavid theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT sztankaymonika theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT boehmechristian theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT fischnallerjulian theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT kiechlstefan theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT holznerbernhard theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT knoflachmichael theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT rumpoldgerhard theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT lehmannjens attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT riedldavid attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT sztankaymonika attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT boehmechristian attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT fischnallerjulian attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT kiechlstefan attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT holznerbernhard attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT knoflachmichael attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease
AT rumpoldgerhard attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease